KL4 (sinapultide) is the first synthetic peptide approved to replace animal-derived lung surfactant, keeping premature babies' lungs from collapsing through an adaptive shape-shifting mechanism.
First syntheticKL4 (sinapultide) is the first peptide-based synthetic replacement for surfactant protein B to be approved for clinical use in respiratory distress
What the researchers found
KL4 (sinapultide) is the first synthetic peptide designed to replace surfactant protein B in lung surfactant therapies. Its formulation, Surfaxin, demonstrated that synthetic peptide-based surfactants can replace animal-derived surfactants for treating respiratory distress syndromes and acute lung injury. Structural studies revealed KL4 has adaptive helical properties — its shape changes depending on lipid environment and pH — with a five-amino-acid repeat pattern that enables it to interact differently with various lipid layers.
This structural plasticity appears to be key to how KL4 helps form stable DPPC monolayers at the air-water interface in the lungs — the same function that natural surfactant protein B performs to keep lung air sacs from collapsing.
Why it matters
Premature babies and patients with acute lung injury need surfactant therapy to keep their lungs from collapsing. Current treatments use surfactant extracted from cow or pig lungs, which raises supply, safety, and consistency concerns. A fully synthetic peptide-based alternative could eliminate animal sourcing, standardize production, and potentially expand access to a life-saving therapy — especially important for neonatal intensive care units worldwide.
The numbers in context
KL4 = penta-residue repeat peptide · first FDA-approved peptide-based surfactant · replaces surfactant protein B
How the study worked
Review of published research on KL4 (sinapultide) structure, function, and clinical application as a synthetic lung surfactant, including molecular characterization studies using biophysical methods to understand peptide-lipid interactions.
Who was studied
Premature infants with respiratory distress syndrome and patients with acute lung injury
What this study cannot tell us
This is a review focused on one peptide (KL4) and its structural mechanism. Clinical comparison data between synthetic and animal-derived surfactants across different patient populations is limited. The molecular characterization is detailed but translating structural insights to improved clinical formulations remains an ongoing challenge.
How to read the evidence
This is a focused review in Current Opinion in Chemical Biology covering the molecular basis and clinical development of KL4. The peptide has FDA approval (strong clinical evidence), though this review focuses primarily on structural characterization rather than clinical outcomes data.
When this study was published
Published in 2016 in Current Opinion in Chemical Biology. KL4 and Surfaxin development has continued since publication, and the structural insights described remain foundational for synthetic surfactant research.
The bigger picture
Replacing animal-derived biological products with synthetic peptides is a recurring theme in medicine — from insulin to lung surfactant. KL4 represents a proof of concept that synthetic peptides can reproduce complex biological functions in the lungs. Understanding how its adaptive structure works could inform design of next-generation surfactant peptides with improved properties, and the synthetic approach could make surfactant therapy more accessible in resource-limited settings where animal-derived products are expensive or unavailable.
Questions still open
- How does Surfaxin's clinical efficacy compare head-to-head with animal-derived surfactants like Survanta and Curosurf?
- Can KL4's adaptive helical mechanism be engineered into improved peptide surfactants with better performance?
- Could synthetic peptide surfactants be effective for COVID-related and other forms of acute respiratory distress syndrome in adults?
Common questions
Why do premature babies need surfactant therapy?
What makes KL4 different from animal-derived surfactant?
Read the original research
Peptide-based synthetic pulmonary surfactant for the treatment of respiratory distress disorders.
Current opinion in chemical biology, 32, 22-8
Citation
Braide-Moncoeur, Otonye; Tran, Nhi T; Long, Joanna R. (2016). Peptide-based synthetic pulmonary surfactant for the treatment of respiratory distress disorders.. Current opinion in chemical biology, 32, 22-8. https://doi.org/10.1016/j.cbpa.2016.02.012